Multiple Myeloma (Kahlers Disease) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, Multiple Myeloma (Kahlers Disease) - Pipeline Review, H1 2012, provides an overview of the Multiple Myeloma (Kahlers Disease) therapeutic pipeline. This report provides information on the therapeutic development for Multiple Myeloma (Kahlers Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahlers Disease). Multiple Myeloma (Kahlers Disease) - Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Multiple Myeloma (Kahlers Disease).
- A review of the Multiple Myeloma (Kahlers Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Multiple Myeloma (Kahlers Disease) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahlers Disease).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahlers Disease) pipeline depth and focus of Multiple Myeloma (Kahlers Disease) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables 8
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Multiple Myeloma (Kahlers Disease) Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Multiple Myeloma (Kahlers Disease) 15
Multiple Myeloma (Kahlers Disease) Therapeutics under Development by Companies 17
Multiple Myeloma (Kahlers Disease) Therapeutics under Investigation by Universities/Institutes 25
Late Stage Products 37
Comparative Analysis 37
Mid Clinical Stage Products 38
Comparative Analysis 38
Early Clinical Stage Products 39
Comparative Analysis 39
Discovery and Pre-Clinical Stage Products 40
Comparative Analysis 40
Multiple Myeloma (Kahlers Disease) Therapeutics – Products under Development by Companies 41
Multiple Myeloma (Kahlers Disease) Therapeutics – Products under Investigation by Universities/Institutes 53
Companies Involved in Multiple Myeloma (Kahlers Disease) Therapeutics Development 89
Bristol-Myers Squibb Company 89
Johnson & Johnson 90
Kyowa Hakko Kirin Co., Ltd. 91
Abbott Laboratories 92
Eli Lilly and Company 93
Viralytics Ltd. 94
GlaxoSmithKline plc 95
Seattle Genetics, Inc. 96
Genentech, Inc. 97
Gilead Sciences, Inc. 98
Biotest AG 99
Merck & Co., Inc. 100
Micromet, Inc. 101
Takeda Pharmaceutical Company Limited 102
BioSante Pharmaceuticals, Inc. 103
ZIOPHARM Oncology, Inc. 104
Millennium Pharmaceuticals, Inc. 105
Novartis AG 106
Cephalon, Inc. 107
Human Genome Sciences, Inc. 108
ImmunoGen, Inc. 109
Pfizer Inc. 110
Sunesis Pharmaceuticals, Inc. 111
SuperGen, Inc. 112
Genmab A/S 113
Cyclacel Pharmaceuticals Inc. 114
Celgene Corporation 115
Onyx Pharmaceuticals, Inc. 116
Incyte Corporation 117
Geron Corporation 118
MannKind Corporation 119
Merck KGaA 120
4SC AG 121
EntreMed, Inc. 122
Innate Pharma SA 148
Piramal Life Sciences Limited 149
SymBio Pharmaceuticals Limited 150
Chroma Therapeutics Ltd. 151
Avaris 152
Abiogen Pharma S.p.A. 153
Acceleron Pharma, Inc. 154
Aquinox Pharmaceuticals Inc. 155
Coronado Biosciences, Inc. 156
Arno Therapeutics, Inc. 157
Vaccinex, Inc. 158
CanBas Co., Ltd. 159
NovImmune SA 160
Axelar AB 161
Immune System Therapeutics Ltd. 162
Concert Pharmaceuticals, Inc. 163
NOXXON Pharma AG 164
Xencor, Inc. 165
Acetylon Pharmaceuticals, Inc. 166
Tragara Pharmaceuticals, Inc. 167
PharmaMar, S.A. 168
AB Science 169
Biokine Therapeutics Ltd. 170
Cylene Pharmaceuticals, Inc. 171
Nereus Pharmaceuticals, Inc. 172
AVEO Pharmaceuticals, Inc. 173
EUSA Pharma, Inc. 174
TAU Therapeutics, LLC 175
Immunovative Therapies, Ltd. 176
Multiple Myeloma (Kahlers Disease) – Therapeutics Assessment 177
Assessment by Monotherapy Products 177
Assessment by Combination Products 178
Assessment by Route of Administration 179
Assessment by Molecule Type 182
Drug Profiles 185
Perifosine - Drug Profile 185
LBH589 - Drug Profile 186
Carfilzomib - Drug Profile 188
Elotuzumab - Drug Profile 190
Aplidin - Drug Profile 192
Velcade + Cyclophosphamide + Dexamethasone - Drug Profile 193
Zolinza - Drug Profile 195
Velcade + Thalidomide + Dexamethasone - Drug Profile 197
Velcade + Dexamethasone - Drug Profile 199
Aplidin + Dexamethasone - Drug Profile 200
LBH589 + Bortezomib + Dexamethasone - Drug Profile 201
Revlimid + Dexamethasone - Drug Profile 203
Actimid + Dexamethasone - Drug Profile 205
Carfilzomib + Revlimid + Dexamethasone - Drug Profile 206
Actimid - Drug Profile 207
Tanespimycin + Velcade - Drug Profile 208
Melphalan + Prednisolone + Thalidomide - Drug Profile 210
Perifosine + Velcade + Dexamethasone - Drug Profile 211
Zolinza + Bortezomib - Drug Profile 212
LBH589 + Bortezomib - Drug Profile 213
Revlimid + Melphalan + Prednisone - Drug Profile 214
HuLuc63 + Lenalidomide + Dexamethasone - Drug Profile 215
Prednisolone - Drug Profile 218
Masitinib + Velcade + Dexamethasone - Drug Profile 219
Multiple Myeloma (Kahlers Disease) Therapeutics – Drug Profile Updates 220
Multiple Myeloma (Kahlers Disease) Therapeutics – Discontinued Products 233
Multiple Myeloma (Kahlers Disease) Therapeutics - Dormant Products 240
Multiple Myeloma (Kahlers Disease) – Product Development Milestones 262
Featured News & Press Releases 262
Jan 06, 2012: Immune System Therapeutics Announce Recruitment Of Patients With Kappa-Type Myeloma In Phase II Trial Of MDX-1097 262
Dec 26, 2011: SymBio Initiates Phase II Trial Of Bendamustine HCl In Multiple Myeloma In Japan 262
Dec 19, 2011: Patrys Provides Update On Upcoming Clinical Trial Program In Multiple Myeloma Patients 263
Dec 13, 2011: Presentations Highlight Results Of Studies With MLN9708, First Oral Proteasome Inhibitor In Early Stage Clinical Trials In Multiple Myeloma 264
Dec 13, 2011: Phase III Study Evaluating REVLIMID In Patients With High-Risk Smoldering Multiple Myeloma Presented At ASH 266
Dec 12, 2011: Celgene Announces Phase II Study Evaluates Clinical Benefit Of Pomalidomide In Heavily Pre-treated Patients With Multiple Myeloma 267
Dec 12, 2011: Acetylon Announces Publication Of Preclinical Pharmacokinetic, Pharmacodynamic And Bone Disease Results for ACY-1215 in Multiple Myeloma 268
Dec 12, 2011: BioInvent Presents New Preclinical Data Of BI-505 At American Society Of Hematology Annual Meeting 269
Dec 12, 2011: Biotest’s Clinical Development Of BT-062 In Multiple Myeloma Expands Into Combination Therapy 270
Dec 12, 2011: Phase III Study With REVLIMID Continuous Therapy Demonstrates Statistically Significant Improvement In Progression-Free Survival For Patients Newly Diagnosed With Multiple Myeloma 271
Appendix 273
Methodology 273
Coverage 273
Secondary Research 273
Primary Research 273
Expert Panel Validation 274
Contact Us 274
Disclaimer 274

List of Tables

Number of Products Under Development for Multiple Myeloma (Kahlers Disease), H1 2012 15
Products under Development for Multiple Myeloma (Kahlers Disease) – Comparative Analysis, H1 2012 16
Number of Products under Development by Companies, H1 2012 18
Number of Products under Investigation by Universities/Institutes, H1 2012 26
Comparative Analysis by Late Stage Development, H1 2012 37
Comparative Analysis by Mid Clinical Stage Development, H1 2012 38
Comparative Analysis by Early Clinical Stage Development, H1 2012 39
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 40
Products under Development by Companies, H1 2012 41
Products under Investigation by Universities/Institutes, H1 2012 53
Bristol-Myers Squibb Company, H1 2012 89
Johnson & Johnson, H1 2012 90
Kyowa Hakko Kirin Co., Ltd., H1 2012 91
Abbott Laboratories, H1 2012 92
Eli Lilly and Company, H1 2012 93
Viralytics Ltd., H1 2012 94
GlaxoSmithKline plc, H1 2012 95
Seattle Genetics, Inc., H1 2012 96
Genentech, Inc., H1 2012 97
Gilead Sciences, Inc., H1 2012 98
Biotest AG, H1 2012 99
Merck & Co., Inc., H1 2012 100
Micromet, Inc., H1 2012 101
Takeda Pharmaceutical Company Limited, H1 2012 102
BioSante Pharmaceuticals, Inc., H1 2012 103
ZIOPHARM Oncology, Inc., H1 2012 104
Millennium Pharmaceuticals, Inc., H1 2012 105
Novartis AG, H1 2012 106
Cephalon, Inc., H1 2012 107
Human Genome Sciences, Inc., H1 2012 108
ImmunoGen, Inc., H1 2012 109
Pfizer Inc., H1 2012 110
Sunesis Pharmaceuticals, Inc., H1 2012 111
SuperGen, Inc., H1 2012 112
Genmab A/S, H1 2012 113
Cyclacel Pharmaceuticals Inc., H1 2012 114
Celgene Corporation, H1 2012 115
Onyx Pharmaceuticals, Inc., H1 2012 116
Incyte Corporation, H1 2012 117
Geron Corporation, H1 2012 118
MannKind Corporation, H1 2012 119
Merck KGaA, H1 2012 120
4SC AG, H1 2012 121
EntreMed, Inc., H1 2012 122
GENTIUM S.p.A., H1 2012 123
Celldex Therapeutics, Inc., H1 2012 124
AEterna Zentaris Inc., H1 2012 125
ImmunoCellular Therapeutics, Ltd., H1 2012 126
IMMUNOMEDICS, INC, H1 2012 127
Ligand Pharmaceuticals Incorporated, H1 2012 128
Avalon Pharmaceuticals, Inc., H1 2012 129
Cleveland BioLabs, Inc., H1 2012 130
Oncolytics Biotech Inc., H1 2012 131
Compugen Ltd., H1 2012 132
Patrys Limited, H1 2012 133
Curis, Inc., H1 2012 134
Keryx Biopharmaceuticals, Inc., H1 2012 135
Alexion Pharmaceuticals, Inc., H1 2012 136
Telik, Inc., H1 2012 137
CytRx Corporation, H1 2012 138
Pharmacyclics, Inc., H1 2012 139
Array BioPharma Inc., H1 2012 140
MorphoSys AG, H1 2012 141
BioInvent International AB, H1 2012 142
Senesco Technologies, Inc., H1 2012 143
Choongwae Pharma Corp, H1 2012 144
Quest PharmaTech Inc., H1 2012 145
Threshold Pharmaceuticals, Inc., H1 2012 146
CrystalGenomics, Inc., H1 2012 147
Innate Pharma SA, H1 2012 148
Piramal Life Sciences Limited, H1 2012 149
SymBio Pharmaceuticals Limited, H1 2012 150
Chroma Therapeutics Ltd., H1 2012 151
Avaris, H1 2012 152
Abiogen Pharma S.p.A., H1 2012 153
Acceleron Pharma, Inc., H1 2012 154
Aquinox Pharmaceuticals Inc., H1 2012 155
Coronado Biosciences, Inc., H1 2012 156
Arno Therapeutics, Inc., H1 2012 157
Vaccinex, Inc., H1 2012 158
CanBas Co., Ltd., H1 2012 159
NovImmune SA, H1 2012 160
Axelar AB, H1 2012 161
Immune System Therapeutics Ltd., H1 2012 162
Concert Pharmaceuticals, Inc., H1 2012 163
NOXXON Pharma AG, H1 2012 164
Xencor, Inc., H1 2012 165
Acetylon Pharmaceuticals, Inc., H1 2012 166
Tragara Pharmaceuticals, Inc., H1 2012 167
PharmaMar, S.A., H1 2012 168
AB Science, H1 2012 169
Biokine Therapeutics Ltd., H1 2012 170
Cylene Pharmaceuticals, Inc., H1 2012 171
Nereus Pharmaceuticals, Inc., H1 2012 172
AVEO Pharmaceuticals, Inc., H1 2012 173
EUSA Pharma, Inc., H1 2012 174
TAU Therapeutics, LLC, H1 2012 175
Immunovative Therapies, Ltd., H1 2012 176
Assessment by Monotherapy Products, H1 2012 177
Assessment by Combination Products, H1 2012 178
Assessment by Stage and Route of Administration, H1 2012 181
Assessment by Molecule Type, H1 2012 184
Multiple Myeloma (Kahlers Disease) Therapeutics – Drug Profile Updates 220
Multiple Myeloma (Kahlers Disease) Therapeutics – Discontinued Products 233
Multiple Myeloma (Kahlers Disease) Therapeutics – Dormant Products 240

List of Figures

Number of Products under Development for Multiple Myeloma (Kahlers Disease), H1 2012 15
Products under Development for Multiple Myeloma (Kahlers Disease) – Comparative Analysis, H1 2012 16
Products under Development by Companies, H1 2012 17
Products under Investigation by Universities/Institutes, H1 2012 25
Late Stage Products, H1 2012 37
Mid Clinical Stage Products, H1 2012 38
Early Clinical Stage Products, H1 2012 39
Discovery and Pre-Clinical Stage Products, H1 2012 40
Assessment by Monotherapy Products, H1 2012 177
Assessment by Combination Products, H1 2012 178
Assessment by Route of Administration, H1 2012 179
Assessment by Stage and Route of Administration, H1 2012 180
Assessment by Molecule Type, H1 2012 182
Assessment by Stage and Molecule Type, H1 2012 183